- Home
- FCNCP vs VCEL Comparison
FCNCP vs VCEL Comparison
Compare FCNCP & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCNCP | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | 18141 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.7B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | FCNCP | VCEL |
|---|---|---|
| Price | $21.24 | $30.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $58.50 |
| AVG Volume (30 Days) | 14.5K | ★ 631.7K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.10 |
| Revenue Next Year | N/A | $17.95 |
| P/E Ratio | ★ N/A | $91.69 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $19.30 | $28.95 |
| 52 Week High | $22.86 | $45.97 |
Technical Indicators
Market Signals| Indicator | FCNCP | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 36.78 |
| Support Level | $20.74 | $29.59 |
| Resistance Level | $21.33 | $38.48 |
| Average True Range (ATR) | 0.25 | 1.54 |
| MACD | -0.02 | -0.17 |
| Stochastic Oscillator | 53.51 | 26.90 |
Price Performance
Historical ComparisonAbout FCNCP First Citizens BancShares Inc.
First Citizens BancShares Inc. is a Raleigh, N.C.-based financial holding company operating through its subsidiary, First-Citizens Bank & Trust Company. It provides comprehensive retail banking, commercial lending, leasing, and wealth management services via a nationwide branch network and digital platforms. In 2023 acquisition of Silicon Valley Bank, it also specializes in banking for tech, healthcare, and innovation firms.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.